Comments
Loading...

Neurocrine Biosciences Analyst Ratings

NBIXNASDAQ
Logo brought to you by Benzinga Data
$120.56
-2.40-1.95%
At close: -
$120.56
0.000.00%
After Hours: 4:00 PM EDT
Consensus Rating1
Buy
Highest Price Target1
$219.00
Lowest Price Target1
$115.00
Consensus Price Target1
$160.28

Neurocrine Biosciences Analyst Ratings and Price Targets | NASDAQ:NBIX | Benzinga

Neurocrine Biosciences Inc has a consensus price target of $160.28 based on the ratings of 25 analysts. The high is $219 issued by Oppenheimer on August 2, 2024. The low is $115 issued by BMO Capital on May 6, 2025. The 3 most-recent analyst ratings were released by Piper Sandler, RBC Capital, and Guggenheim on May 6, 2025, respectively. With an average price target of $154.67 between Piper Sandler, RBC Capital, and Guggenheim, there's an implied 28.29% upside for Neurocrine Biosciences Inc from these most-recent analyst ratings.

Analyst Trends and Forecast
9
Feb
2
Mar
6
Apr
6
1
May
Buy
Hold
Sell
Strong Sell
Analyst Rating and Forecast
12345
4.0
Buy
Strong Buy
Buy
Hold
Sell
Strong Sell

Analyst Firms Making Recommendations1

Piper Sandler
RBC Capital
Guggenheim
BMO Capital
UBS

1calculated from analyst ratings

Analyst Ratings for Neurocrine Biosciences

Buy NowGet Alert
05/06/2025Buy Now27.74%Piper Sandler
David Amsellem75%
$160 → $154ReiteratesOverweight → OverweightGet Alert
05/06/2025Buy Now20.27%RBC Capital
Brian Abrahams31%
$137 → $145MaintainsOutperformGet Alert
05/06/2025Buy Now36.86%Guggenheim
Yatin Suneja47%
$155 → $165MaintainsBuyGet Alert
05/06/2025Buy Now-4.61%BMO Capital
Evan Seigerman62%
$96 → $115MaintainsMarket PerformGet Alert
05/06/2025Buy Now26.08%UBS
Ashwani Verma51%
$137 → $152MaintainsBuyGet Alert
05/06/2025Buy Now32.71%Canaccord Genuity
Sumant Kulkarni34%
$158 → $160MaintainsBuyGet Alert
05/06/2025Buy Now15.3%Needham
Ami Fadia53%
$138 → $139MaintainsBuyGet Alert
04/28/2025Buy Now31.06%Canaccord Genuity
Sumant Kulkarni34%
$163 → $158MaintainsBuyGet Alert
04/24/2025Buy Now53.45%Evercore ISI Group
Cory Kasimov68%
$190 → $185MaintainsOutperformGet Alert
04/22/2025Buy Now39.35%HC Wainwright & Co.
Andrew Fein54%
$185 → $168MaintainsBuyGet Alert
04/15/2025Buy Now14.47%Needham
Ami Fadia53%
→ $138UpgradeHold → BuyGet Alert
04/14/2025Buy Now13.64%RBC Capital
Brian Abrahams31%
$138 → $137UpgradeSector Perform → OutperformGet Alert
04/04/2025Buy Now13.64%UBS
Ashwani Verma51%
$154 → $137MaintainsBuyGet Alert
03/26/2025Buy Now52.62%JP Morgan
Anupam Rama55%
$183 → $184MaintainsOverweightGet Alert
03/07/2025Buy Now24.42%Morgan Stanley
Jeffrey Hung53%
$185 → $150Assumes → OverweightGet Alert
02/24/2025Buy Now53.45%HC Wainwright & Co.
Andrew Fein54%
$185 → $185ReiteratesBuy → BuyGet Alert
02/21/2025Buy Now53.45%HC Wainwright & Co.
Andrew Fein54%
$185 → $185ReiteratesBuy → BuyGet Alert
02/10/2025Buy Now35.2%Guggenheim
Yatin Suneja47%
$165 → $163MaintainsBuyGet Alert
02/10/2025Buy Now53.45%HC Wainwright & Co.
Andrew Fein54%
$190 → $185MaintainsBuyGet Alert
02/07/2025Buy Now22.76%RBC Capital
Brian Abrahams31%
$154 → $148MaintainsSector PerformGet Alert
02/07/2025Buy Now21.93%Wedbush
Laura Chico36%
$157 → $147MaintainsOutperformGet Alert
02/07/2025Buy Now35.2%Canaccord Genuity
Sumant Kulkarni34%
$172 → $163MaintainsBuyGet Alert
02/07/2025Buy Now53.45%HC Wainwright & Co.
Andrew Fein54%
$190 → $185MaintainsBuyGet Alert
02/07/2025Buy NowNeedham
Ami Fadia53%
ReiteratesHold → HoldGet Alert
02/07/2025Buy Now48.47%B of A Securities
Tazeen Ahmad73%
$184 → $179MaintainsBuyGet Alert
02/04/2025Buy Now53.45%Morgan Stanley
Jeffrey Hung53%
$170 → $185MaintainsOverweightGet Alert
01/30/2025Buy Now45.99%UBS
Ashwani Verma51%
$162 → $176MaintainsBuyGet Alert
01/08/2025Buy Now34.37%UBS
Ashwani Verma51%
$142 → $162MaintainsBuyGet Alert
12/23/2024Buy Now32.71%Piper Sandler
David Amsellem75%
$160 → $160ReiteratesOverweight → OverweightGet Alert
12/23/2024Buy Now36.86%Barclays
Carter Gould53%
$160 → $165MaintainsOverweightGet Alert
12/20/2024Buy NowNeedham
Ami Fadia53%
ReiteratesHold → HoldGet Alert
12/16/2024Buy Now22.76%Wedbush
Laura Chico36%
$148 → $148ReiteratesOutperform → OutperformGet Alert
12/16/2024Buy Now57.6%HC Wainwright & Co.
Andrew Fein54%
$190 → $190ReiteratesBuy → BuyGet Alert
11/11/2024Buy NowNeedham
Ami Fadia53%
Reiterates → HoldGet Alert
11/01/2024Buy Now57.6%HC Wainwright & Co.
Andrew Fein54%
$190 → $190ReiteratesBuy → BuyGet Alert
10/31/2024Buy NowNeedham
Ami Fadia53%
Reiterates → HoldGet Alert
10/30/2024Buy NowNeedham
Ami Fadia53%
Reiterates → HoldGet Alert
10/29/2024Buy NowNeedham
Ami Fadia53%
Reiterates → HoldGet Alert
10/17/2024Buy Now-5.44%BMO Capital
Evan Seigerman62%
$128 → $114MaintainsMarket PerformGet Alert
10/10/2024Buy Now28.57%Raymond James
Danielle Brill25%
→ $155Reinstates → OutperformGet Alert
10/08/2024Buy Now10.32%RBC Capital
Brian Abrahams31%
$133 → $133ReiteratesSector Perform → Sector PerformGet Alert
10/04/2024Buy Now10.32%RBC Capital
Brian Abrahams31%
$136 → $133MaintainsSector PerformGet Alert
09/16/2024Buy Now28.57%Cantor Fitzgerald
Charles Duncan69%
$155 → $155ReiteratesOverweight → OverweightGet Alert
09/09/2024Buy Now32.71%Barclays
Carter Gould53%
$180 → $160MaintainsOverweightGet Alert
08/29/2024Buy Now28.57%Cantor Fitzgerald
Charles Duncan69%
$170 → $155MaintainsOverweightGet Alert
08/29/2024Buy Now6.17%BMO Capital
Evan Seigerman62%
$142 → $128MaintainsMarket PerformGet Alert
08/29/2024Buy Now31.88%Piper Sandler
David Amsellem75%
$131 → $159UpgradeNeutral → OverweightGet Alert
08/29/2024Buy Now12.81%RBC Capital
Brian Abrahams31%
$143 → $136MaintainsSector PerformGet Alert
08/29/2024Buy Now57.6%HC Wainwright & Co.
Andrew Fein54%
$190 → $190ReiteratesBuy → BuyGet Alert
08/29/2024Buy NowNeedham
Ami Fadia53%
Reiterates → HoldGet Alert
08/19/2024Buy Now56.77%Jefferies
Akash Tewari41%
$177 → $189MaintainsBuyGet Alert
08/07/2024Buy Now50.13%JP Morgan
Anupam Rama55%
$173 → $181MaintainsOverweightGet Alert
08/05/2024Buy Now57.6%HC Wainwright & Co.
Andrew Fein54%
$160 → $190MaintainsBuyGet Alert
08/02/2024Buy Now18.61%RBC Capital
Brian Abrahams31%
$136 → $143MaintainsSector PerformGet Alert
08/02/2024Buy Now49.3%Guggenheim
Yatin Suneja47%
$170 → $180MaintainsBuyGet Alert
08/02/2024Buy Now31.06%Citigroup
David Hoang68%
$150 → $158MaintainsNeutralGet Alert
08/02/2024Buy Now81.65%Oppenheimer
Jay Olson60%
$216 → $219MaintainsOutperformGet Alert
08/02/2024Buy Now49.3%Barclays
Carter Gould53%
$169 → $180MaintainsOverweightGet Alert
08/02/2024Buy Now49.3%Baird
Brian Skorney57%
$157 → $180MaintainsOutperformGet Alert
08/01/2024Buy NowNeedham
Ami Fadia53%
Reiterates → HoldGet Alert
07/25/2024Buy Now28.57%Cantor Fitzgerald
Charles Duncan69%
$155 → $155ReiteratesOverweight → OverweightGet Alert
07/25/2024Buy NowNeedham
Ami Fadia53%
Reiterates → HoldGet Alert
07/12/2024Buy Now41.01%Morgan Stanley
Jeffrey Hung53%
$160 → $170MaintainsOverweightGet Alert
07/10/2024Buy Now43.5%JP Morgan
Anupam Rama55%
$169 → $173MaintainsOverweightGet Alert
06/12/2024Buy Now32.71%Morgan Stanley
Jeffrey Hung53%
$160 → $160MaintainsOverweightGet Alert
05/29/2024Buy Now26.08%Wedbush
Laura Chico36%
$152 → $152ReiteratesOutperform → OutperformGet Alert
05/28/2024Buy Now60.09%UBS
Ashwani Verma51%
$174 → $193MaintainsBuyGet Alert
05/14/2024Buy Now45.16%Evercore ISI Group
Cory Kasimov68%
→ $175Initiates → OutperformGet Alert
05/03/2024Buy Now24.42%Citigroup
David Hoang68%
$140 → $150MaintainsNeutralGet Alert
05/02/2024Buy Now36.03%Canaccord Genuity
Sumant Kulkarni34%
$154 → $164MaintainsBuyGet Alert
05/02/2024Buy Now41.01%Guggenheim
Yatin Suneja47%
$164 → $170MaintainsBuyGet Alert
05/02/2024Buy Now40.18%Barclays
Carter Gould53%
$150 → $169MaintainsOverweightGet Alert
05/02/2024Buy Now14.47%BMO Capital
Evan Seigerman62%
$129 → $138MaintainsMarket PerformGet Alert
05/02/2024Buy Now79.16%Oppenheimer
Jay Olson60%
$200 → $216MaintainsOutperformGet Alert
05/02/2024Buy Now32.71%HC Wainwright & Co.
Andrew Fein54%
$150 → $160MaintainsBuyGet Alert
05/02/2024Buy NowNeedham
Ami Fadia53%
Reiterates → HoldGet Alert
05/01/2024Buy NowNeedham
Ami Fadia53%
Reiterates → HoldGet Alert
04/24/2024Buy Now24.42%HC Wainwright & Co.
Andrew Fein54%
$150 → $150ReiteratesBuy → BuyGet Alert
04/24/2024Buy Now41.01%Wells Fargo
Mohit Bansal57%
$140 → $170UpgradeEqual-Weight → OverweightGet Alert
04/24/2024Buy Now65.89%Oppenheimer
Jay Olson60%
$200 → $200MaintainsOutperformGet Alert
04/23/2024Buy NowNeedham
Ami Fadia53%
Reiterates → HoldGet Alert
04/17/2024Buy Now21.93%Wedbush
Laura Chico36%
$147 → $147ReiteratesOutperform → OutperformGet Alert
04/10/2024Buy Now28.57%Cantor Fitzgerald
Charles Duncan69%
→ $155ReiteratesOverweight → OverweightGet Alert
03/20/2024Buy Now31.06%JP Morgan
Anupam Rama55%
$148 → $158MaintainsOverweightGet Alert
03/13/2024Buy Now65.89%Oppenheimer
Jay Olson60%
$170 → $200MaintainsOutperformGet Alert
02/23/2024Buy Now22.76%JP Morgan
Anupam Rama55%
$154 → $148MaintainsOverweightGet Alert
02/08/2024Buy Now16.12%Citigroup
David Hoang68%
$141 → $140MaintainsNeutralGet Alert
02/08/2024Buy Now16.12%Mizuho
Uy Ear39%
$116 → $140MaintainsNeutralGet Alert
02/08/2024Buy Now16.12%Wells Fargo
Mohit Bansal57%
$127 → $140MaintainsEqual-WeightGet Alert
01/25/2024Buy Now26.91%Goldman Sachs
Chris Shibutani45%
$134 → $153MaintainsBuyGet Alert
01/23/2024Buy Now24.42%Barclays
Carter Gould53%
$145 → $150MaintainsOverweightGet Alert
12/18/2023Buy Now19.44%Stifel
Paul Matteis5%
$141 → $144MaintainsBuyGet Alert
12/13/2023Buy Now5.34%Wells Fargo
Mohit Bansal57%
$110 → $127MaintainsEqual-WeightGet Alert
12/13/2023Buy Now5.34%Citigroup
David Hoang68%
→ $127Initiates → NeutralGet Alert
12/12/2023Buy Now12.81%Deutsche Bank
Neena Bitritto-Garg61%
→ $136Initiates → BuyGet Alert
12/07/2023Buy Now24.42%Canaccord Genuity
Sumant Kulkarni34%
→ $150ReiteratesBuy → BuyGet Alert
11/10/2023Buy Now-17.05%BMO Capital
Evan Seigerman62%
$111 → $100MaintainsMarket PerformGet Alert
11/10/2023Buy Now0.36%RBC Capital
Brian Abrahams31%
$128 → $121MaintainsSector PerformGet Alert
11/10/2023Buy Now-5.44%Mizuho
Uy Ear39%
$116 → $114MaintainsNeutralGet Alert
11/03/2023Buy Now-3.78%Mizuho
Uy Ear39%
$113 → $116MaintainsNeutralGet Alert

FAQ

Q

What is the target price for Neurocrine Biosciences (NBIX) stock?

A

The latest price target for Neurocrine Biosciences (NASDAQ:NBIX) was reported by Piper Sandler on May 6, 2025. The analyst firm set a price target for $154.00 expecting NBIX to rise to within 12 months (a possible 27.74% upside). 67 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for Neurocrine Biosciences (NBIX)?

A

The latest analyst rating for Neurocrine Biosciences (NASDAQ:NBIX) was provided by Piper Sandler, and Neurocrine Biosciences reiterated their overweight rating.

Q

When was the last upgrade for Neurocrine Biosciences (NBIX)?

A

The last upgrade for Neurocrine Biosciences Inc happened on April 15, 2025 when Needham raised their price target to $138. Needham previously had a hold for Neurocrine Biosciences Inc.

Q

When was the last downgrade for Neurocrine Biosciences (NBIX)?

A

There is no last downgrade for Neurocrine Biosciences.

Q

When is the next analyst rating going to be posted or updated for Neurocrine Biosciences (NBIX)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Neurocrine Biosciences, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Neurocrine Biosciences was filed on May 6, 2025 so you should expect the next rating to be made available sometime around May 6, 2026.

Q

Is the Analyst Rating Neurocrine Biosciences (NBIX) correct?

A

While ratings are subjective and will change, the latest Neurocrine Biosciences (NBIX) rating was a reiterated with a price target of $160.00 to $154.00. The current price Neurocrine Biosciences (NBIX) is trading at is $120.56, which is out of the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.

People Also Watch